Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sun Yat-sen University
To explore the progression-free survival of patients with metastatic triple-negative breast cancer treated with peripheral blood stem cell transplant (PBSCT) followed by high dose chemotherapy.
Age
18–65
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Eastern Cooperative Oncology Group (ECOG) 0 or 1.
Histologically or cytologically proven diagnosis of breast cancer with evidence of locally recurrent or metastatic disease.
Documentation of estrogen and progestin receptor (ER/PR) negative status and HER2/neu receptor negative status (ie, FISH negative or immunohistochemistry 0 or +1).
Obtained complete response or Good partial response after first line chemotherapy.
Normal organ function required prior to study entry.
Willingness to comply with treatment plans and other study procedures.
You may not be if
Uncontrolled central nervous system (CNS) involvement with disease
Fertile women unwilling to use contraceptive techniques during treatment
Females who are pregnant
Organ dysfunction.
Patients may not be receiving any other investigational agents.
Clareo Health | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer
